07:00 , Jun 23, 2016 |  BC Innovations  |  Tools & Techniques

Home is in the placenta

Many drug developers have avoided stepping into what they see as the high risk area of pregnancy-associated complications, leaving diseases such as preeclampsia and fetal growth restriction with little innovation and few treatment options. By...
07:00 , Apr 21, 2016 |  BC Innovations  |  Product R&D

A1M for preeclampsia

A poor understanding of disease biology and a challenging development pathway have kept most drug developers away from the serious pregnancy complication preeclampsia, but A1M Pharma AB has a new approach with a first-in-class therapy...
07:00 , Mar 24, 2016 |  BC Innovations  |  Product R&D

Liver-bound

Ionis Pharmaceuticals Inc. is retooling its antisense technology with a sugar-based conjugate that boosts uptake into liver cells. By tapping the power of GalNAc sugars to latch onto hepatocyte receptors, the company believes it can...
07:00 , Oct 16, 2014 |  BC Innovations  |  Targets & Mechanisms

Alnylam interrupts preeclampsia

Preeclampsia often involves overactivation of the renin-angiotensin system that regulates blood pressure, but inhibiting the pathway is not possible because it would be toxic to the fetus. Alnylam Pharmaceuticals Inc. has developed an siRNA conjugate...
07:00 , Oct 6, 2014 |  BC Week In Review  |  Clinical News

Alnylam preclinical data

In a rat model of preeclampsia, subcutaneous ALN-AGT led to >90% knockdown of maternal angiotensinogen (AGT) in the liver with no detectable evidence of fetal drug exposure. ALN-AGT also significantly reduced mean arterial blood...
08:00 , Feb 14, 2013 |  BC Innovations  |  Distillery Therapeutics

Indication: Cancer

Indication Target/marker/pathway Summary Licensing status Publication and contact information Cancer Non-small cell lung cancer (NSCLC) Angiotensinogen (AGT); angiotensin-converting enzyme (ACE) Patient tissue and mouse studies suggest ACE...
07:00 , May 7, 2009 |  BC Innovations  |  Cover Story

New axis in hypertension

U.S. and European researchers have found that deleting the prostaglandin F receptor can lower both blood pressure and atherosclerotic plaque formation in mice.1 Now that the receptor has been shown to be involved in the...
07:00 , May 28, 2007 |  BioCentury  |  Strategy

Tekturna con and pro

Tekturna aliskiren from Novartis AG and Speedel AG already faces an uphill marketing battle in the hypertension space, as the first-in-class renin inhibitor has a higher price tag than the slew of generic medicines in...
08:00 , Nov 20, 2000 |  BC Week In Review  |  Company News

Amersham Pharmacia Biotech Inc., University of Washington deal

Amersham, the life sciences business of Nycomed Amersham plc (NYE; LSE:NAM, Uppsala, Sweden), granted the university early access to its SNiPer Scoring System for use in examining genetic variations in the angiotensinogen gene,...
07:00 , May 8, 2000 |  BC Week In Review  |  Clinical News

Angiotensinogen gene and p16 tumor suppressor gene regulatory update

MYGN received U.S. Patent No. 5,998,145 covering the use of the angiotensinogen (AGT) gene in MYGN's CardiaRisk test to determine predisposition to hypertension. MYGN also received U.S. Patent No. 6,037,462 covering the p16 (MTS1/INK4)...